Loading clinical trials...
Loading clinical trials...
A Phase III, Randomized, Open-label, Active Vaccine-controlled Crossover Study to Evaluate the Reactogenicity, Safety and Immune Response of Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Girls From 9 to 17 Years of Age, and in Non-pregnant Adult Women From 18 to 49 Years of Age
Conditions
Interventions
RSV MAT vaccine
dTpa vaccine
Locations
2
United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Beaumont, Texas, United States
Start Date
February 2, 2022
Primary Completion Date
August 3, 2022
Completion Date
August 3, 2022
Last Updated
April 7, 2023
NCT07220109
NCT07092865
NCT07239583
NCT06534892
NCT04919109
NCT05705440
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions